专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008012110A3 ANNELLATED PYRROLE COMPOUNDS FOR CANCER MANAGEMENT 审中-公开
标题翻译：新型吡咯类化合物用于癌症治疗
公开(公告)号：WO2008012110A3
公开(公告)日：2008-04-10
申请号：PCT/EP2007006735
申请日：2007-07-30
申请人： MERCKLE GMBH , LAUFER STEFAN , GUARNIERI TIZIANA , TAVOLARI SIMONA , TOMASI VITTORIO , PALAZZINI ERNESTO , BARBANTI MIRIAM
发明人： LAUFER STEFAN , GUARNIERI TIZIANA , TAVOLARI SIMONA , TOMASI VITTORIO , PALAZZINI ERNESTO , BARBANTI MIRIAM
IPC分类号： A61K31/407 , A61P35/00
CPC分类号： A61K31/407
摘要： The present invention relates to the use of annellated pyrrole compounds and in particular ML3000 (licofelone), salts or derivatives thereof, for cancer management, and in general to the use of a compound of Formula (I): wherein the variables have the meanings given in the present description, for the prevention and/or treatment of neoplasia, in particular neoplasia selected from the group consisting of papilloma, carcinoma, adenoma and adenocarcinoma, e. g. human airway or colorectal carcinoma, preferably fast-growing, multidrug resistant and/or COX-2 negative neoplasia. The invention further relates to pharmaceutical compositions for the aforesaid purposes, comprising annellated pyrrole compounds and in particular ML3000 (licofelone), optical isomers, salts or derivatives thereof, as well as to a method of treating and/or preventing neoplasia and/or restoring the ability to undergo apoptosis in a cell having lost the same. This treatment ameliorates, diminishes, actively treats, reverses or prevents any disease related to insufficient apoptosis, in particular neoplasia, and it may be combined with irradiation, heating and treatment with a cytotoxic agent for preventive and/or curative purposes.
摘要翻译：本发明涉及口服吡咯化合物，特别是ML3000（Licofelone），其盐或衍生物用于癌症治疗，并且一般涉及式（I）化合物的用途：其中变量具有给定的含义在本说明书中，用于预防和/或治疗瘤形成，特别是选自由乳头瘤，癌，腺瘤和腺癌组成的组的瘤形成， G。人气道或结直肠癌，优选快速生长，多药耐药性和/或COX-2阴性瘤形成。本发明进一步涉及用于上述目的的药物组合物，其包含螺化的吡咯化合物，特别是ML3000（Licofelone），其旋光异构体，盐或衍生物，以及治疗和/或预防瘤形成和/或恢复在失去细胞的细胞中发生细胞凋亡的能力。该治疗改善，减少，积极治疗，逆转或预防任何与细胞凋亡不足有关的疾病，特别是瘤形成，并且可以将其与辐射，加热和用细胞毒剂治疗组合用于预防和/或治疗目的。

2. 发明申请

WO2006094737A8 GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN 审中-公开
标题翻译：含有RIFAXIMIN的胃肠药物制剂
公开(公告)号：WO2006094737A8
公开(公告)日：2007-11-15
申请号：PCT/EP2006002022
申请日：2006-03-06
申请人： ALFA WASSERMANN SPA , VISCOMI GIUSEPPE C , PALAZZINI ERNESTO , ZAMBONI VILLIAM , PANTALEO MARIA ROSARIA
发明人： VISCOMI GIUSEPPE C , PALAZZINI ERNESTO , ZAMBONI VILLIAM , PANTALEO MARIA ROSARIA
IPC分类号： A61K9/16 , A61K31/395 , A61K31/44
CPC分类号： A61K9/1652 , A61K9/0095 , A61K9/1635 , A61K9/2027 , A61K9/2054 , A61K9/28 , A61K9/5026 , A61K9/5073 , A61K31/395 , A61K31/437 , A61K31/44
摘要： The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.
摘要翻译：本发明的目的是由药物制剂组成，其中含有利用不溶性聚合物在pH值介于1.5和4.0之间并且可溶于pH值在5.0和7.5之间的不溶性聚合物的微粒形式的利福昔明，其制备方法及其在制备中的用途用于治疗炎症性肠病（IBD）和主要是克罗恩病的药物制剂。

3. 发明申请

WO2006094737A3 GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN 审中-公开
标题翻译：含Rifaximin的胃肠外用药物制剂
公开(公告)号：WO2006094737A3
公开(公告)日：2007-02-15
申请号：PCT/EP2006002022
申请日：2006-03-06
申请人： ALFA WASSERMANN SPA , VISCOMI GIUSEPPE C , PALAZZINI ERNESTO , ZAMBONI VILLIAM , PANTALEO MARIA ROSARIA
发明人： VISCOMI GIUSEPPE C , PALAZZINI ERNESTO , ZAMBONI VILLIAM , PANTALEO MARIA ROSARIA
IPC分类号： A61K9/16 , A61K31/395 , A61K31/44
CPC分类号： A61K9/1652 , A61K9/0095 , A61K9/1635 , A61K9/2027 , A61K9/2054 , A61K9/28 , A61K9/5026 , A61K9/5073 , A61K31/395 , A61K31/437 , A61K31/44
摘要： The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.
摘要翻译：本发明的目的由药物制剂组成，所述药物制剂包含微粒剂形式的利福昔明，其通过pH值为1.5-4.0的不溶性聚合物胃耐受，并且可溶于pH值5.0-7.5，通过它们的制备以及它们用于制备用于治疗炎症性肠病（IBD）和主要克罗恩氏病的药物制剂。

4. 发明申请

WO0193850B1 METHODS AND COMPOSITIONS USING SULODEXIDE FOR THE TREATMENT OF DIABETIC NEPHROPATHY 审中-公开
标题翻译：使用硫代酸治疗糖尿病性肾病的方法和组合
公开(公告)号：WO0193850B1
公开(公告)日：2003-02-20
申请号：PCT/US0118411
申请日：2001-06-06
申请人： ALFA WASSERMANN INC , PALAZZINI ERNESTO , GAMBARO GIOVANNI
发明人： PALAZZINI ERNESTO , GAMBARO GIOVANNI
IPC分类号： A61K9/10 , A61K9/20 , A61K9/48 , A61K9/64 , A61K31/00 , A61K31/70 , A61K31/726 , A61P13/12 , C08B37/00 , A61K31/737
CPC分类号： A61K31/727 , A61K9/48 , A61K31/70 , A61K31/726 , A61K31/737 , A61K35/38 , A61K2300/00
摘要： The present invention provides oral formulations of Sulodexide for the treatment of diabetic nephropathy in patients with both insulin dependent and non-insulin dependent diabetes mellitus. Oral formulations containing doses adapted for administration to obtain a reduction in albumin excretion in patients with both micro and macro albuminuria and to produce lasting improvement in albumin excretion rate are provided. Methods of treating diabetic nephropathy using these formulations are also provided.
摘要翻译：本发明提供了用于治疗胰岛素依赖性和非胰岛素依赖性糖尿病患者的糖尿病肾病的口服制剂。提供含有适于施用以获得微量和大量白蛋白尿的患者中白蛋白排泄减少并且产生白蛋白排泄率持续改善的剂量的口服制剂。还提供了使用这些制剂治疗糖尿病肾病的方法。

5. 发明申请

WO0193850A2 METHODS AND COMPOSITIONS USING SULODEXIDE FOR THE TREATMENT OF DIABETIC NEPHROPATHY 审中-公开
标题翻译：使用硫代酸治疗糖尿病性肾病的方法和组合
公开(公告)号：WO0193850A2
公开(公告)日：2001-12-13
申请号：PCT/US0118411
申请日：2001-06-06
申请人： ALFA WASSERMANN INC , PALAZZINI ERNESTO , GAMBARO GIOVANNI
发明人： PALAZZINI ERNESTO , GAMBARO GIOVANNI
IPC分类号： A61K9/10 , A61K9/20 , A61K9/48 , A61K9/64 , A61K31/00 , A61K31/70 , A61K31/726 , A61P13/12 , C08B37/00
CPC分类号： A61K31/727 , A61K9/48 , A61K31/70 , A61K31/726 , A61K31/737 , A61K35/38 , A61K2300/00
摘要： The present invention provides oral formulations of Sulodexide for the treatment of diabetic nephropathy in patients with both insulin dependent and non-insulin dependent diabetes mellitus. Oral formulations containing doses adapted for administration to obtain a reduction in albumin excretion in patients with both micro and macro albuminuria and to produce lasting improvement in albumin excretion rate are provided. Methods of treating diabetic nephropathy using these formulations are also provided.
摘要翻译：本发明提供了用于治疗胰岛素依赖性和非胰岛素依赖性糖尿病患者的糖尿病肾病的口服制剂。提供含有适于施用以获得微量和大量白蛋白尿的患者中白蛋白排泄减少并且产生白蛋白排泄率持续改善的剂量的口服制剂。还提供了使用这些制剂治疗糖尿病肾病的方法。

6. 发明专利

CA2657815A1 ANNELLATED PYRROLE COMPOUNDS FOR CANCER MANAGEMENT 未知
公开(公告)号：CA2657815A1
公开(公告)日：2008-01-31
申请号：CA2657815
申请日：2007-07-30
申请人： MERCKLE GMBH
发明人： LAUFER STEFAN , GUARNIERI TIZIANA , TOMASI VITTORIO , TAVOLARI SIMONA , BARBANTI MIRIAM , PALAZZINI ERNESTO
IPC分类号： A61K31/407 , A61P35/00
摘要： The present invention relates to the use of annellated pyrrole compounds and in particular ML3000 (licofelone), salts or derivatives thereof, for can cer management, and in general to the use of a compound of Formula (I): wher ein the variables have the meanings given in the present description, for th e prevention and/or treatment of neoplasia, in particular neoplasia selected from the group consisting of papilloma, carcinoma, adenoma and adenocarcino ma, e. g. human airway or colorectal carcinoma, preferably fast-growing, mul tidrug resistant and/or COX-2 negative neoplasia. The invention further rela tes to pharmaceutical compositions for the aforesaid purposes, comprising an nellated pyrrole compounds and in particular ML3000 (licofelone), optical is omers, salts or derivatives thereof, as well as to a method of treating and/ or preventing neoplasia and/or restoring the ability to undergo apoptosis in a cell having lost the same. This treatment ameliorates, diminishes, active ly treats, reverses or prevents any disease related to insufficient apoptosi s, in particular neoplasia, and it may be combined with irradiation, heating and treatment with a cytotoxic agent for preventive and/or curative purpose s.

7. 发明专利

AU2007278431A1 Annellated pyrrole compounds for cancer management 未知
公开(公告)号：AU2007278431A1
公开(公告)日：2008-01-31
申请号：AU2007278431
申请日：2007-07-30
申请人： MERCKLE GMBH
发明人： PALAZZINI ERNESTO , TAVOLARI SIMONA , TOMASI VITTORIO , LAUFER STEFAN , GUARNIERI TIZIANA , BARBANTI MIRIAM
IPC分类号： A61K31/407 , A61P35/00
摘要： The present invention relates to the use of annellated pyrrole compounds and in particular ML3000 (licofelone) salts or derivatives thereof, for cancer management, and in general to the use of a compound of Formula (I): wherein the variables have the meanings given in the present description, for the prevention and/or treatment of neoplasia, in particular neoplasia selected from the group consisting of papilloma, carcinoma, adenoma and adenocarcinoma, e. g. human airway or colorectal carcinoma, preferably fast-growing, multidrug resistant and/or COX-2 negative neoplasia. The invention further relates to pharmaceutical compositions for the aforesaid purposes, comprising annellated pyrrole compounds and in particular ML3000 (licofelone), optical isomers, salts or derivatives thereof, as well as to a method of treating and/or preventing neoplasia and/or restoring the ability to undergo apoptosis in a cell having lost the same. This treatment ameliorates, diminishes, actively treats, reverses or prevents any disease related to insufficient apoptosis, in particular neoplasia, and it may be combined with irradiation, heating and treatment with a cytotoxic agent for preventive and/or curative purposes.

8. 发明专利

NZ574197A ANNELLATED PYRROLE COMPOUNDS FOR CANCER MANAGEMENT 未知
公开(公告)号：NZ574197A
公开(公告)日：2012-02-24
申请号：NZ57419707
申请日：2007-07-30
申请人： MERCKLE GMBH
发明人： LAUFER STEFAN , GUARNIERI TIZIANA , TAVOLARI SIMONA , TOMASI VITTORIO , PALAZZINI ERNESTO , BARBANTI MIRIAM
IPC分类号： A61K31/407 , A61P35/00
摘要： Disclosed is the use of [6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid for treating neoplasia.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式